Prescription Medicine. Fully Funded.
Modified-release formulation of nitrofurantoin.
For the treatment of uncomplicated urinary tract infections.
Twice daily nitrofurantoin, MacroBID® contains:
-
25% nitrofurantoin macrocrystals
-
75% nitrofurantoin monohydrate
Adults and Pediatric Patients Over 12 Years:100mg capsule twice daily, with food.1
This site is intended for New Zealand consumers only.
References: 1. MacroBID New Zealand Data sheet, available at https://www.medsafe.govt.nz/Profs/datasheet/m/macrobidcap.pdf
MacroBID® Modified Release Capsule 100mg (as 25 mg nitrofurantoin macrocrystals and 75 mg of nitrofurantoin (as 80.7 mg of monohydrate)), is a Prescription Medicine. For the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Therapy with nitrofurantoin may be initiated before results of culture and susceptibility tests are known; therapy should be continued or altered, as appropriate, in accordance with results of the tests. Adults, and children over 12 years take one 100mg capsule every 12 hours for seven days, with food. MacroBID® has risks and benefits. Ask your doctor if MacroBID® is right for you. Use strictly as directed. If symptoms persist see your doctor. MacroBID® is a fully funded medicine from 1 March 2021. Normal doctor’s charges and pharmacy fees apply. For product details check the Consumer Medicine Information, CMI, at www.medsafe.govt.nz. MacroBID® is a registered trademark of Alvogen. Distributed in New Zealand by Te Arai BioFarma Ltd, Auckland NZ. TAPS 2149LG